{"protocolSection": {"identificationModule": {"nctId": "NCT00881530", "orgStudyIdInfo": {"id": "1245.24"}, "secondaryIdInfos": [{"id": "2008-007938-21", "type": "EUDRACT_NUMBER", "domain": "EudraCT"}], "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension", "officialTitle": "A 78 Week Open Label Extension to Trials Assessing the Safety and Efficacy of BI 10773 as Monotherapy or in Combination With Metformin in Type 2 Diabetic Patients"}, "statusModule": {"statusVerifiedDate": "2014-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-03"}, "primaryCompletionDateStruct": {"date": "2011-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-04-14", "studyFirstSubmitQcDate": "2009-04-14", "studyFirstPostDateStruct": {"date": "2009-04-15", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-05-16", "resultsFirstSubmitQcDate": "2014-05-16", "resultsFirstPostDateStruct": {"date": "2014-06-16", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-05-16", "lastUpdatePostDateStruct": {"date": "2014-06-16", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The objective of the current study is to investigate the safety and efficacy of BI 10773 in 2 different doses compared to Metformin or to Sitagliptin given for 78 weeks in different modalities of treatment in patients with type 2 diabetes mellitus."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 660, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sitagliptin", "type": "ACTIVE_COMPARATOR", "description": "100 mg", "interventionNames": ["Drug: Sitagliptin"]}, {"label": "Metformin", "type": "ACTIVE_COMPARATOR", "description": "2000 mg", "interventionNames": ["Drug: Metformin"]}, {"label": "BI 10773 X mg", "type": "EXPERIMENTAL", "description": "lower dose", "interventionNames": ["Drug: BI 10773"]}, {"label": "BI 10773 Y mg", "type": "EXPERIMENTAL", "description": "higher dose", "interventionNames": ["Drug: BI 10773"]}], "interventions": [{"type": "DRUG", "name": "BI 10773", "description": "BI 10773 high dose once daily", "armGroupLabels": ["BI 10773 Y mg"]}, {"type": "DRUG", "name": "Metformin", "description": "open label comparator", "armGroupLabels": ["Metformin"]}, {"type": "DRUG", "name": "BI 10773", "description": "BI 10773 low dose once daily", "armGroupLabels": ["BI 10773 X mg"]}, {"type": "DRUG", "name": "Sitagliptin", "description": "open label comparator", "armGroupLabels": ["Sitagliptin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Hypoglycaemic Events", "description": "Investigator defined Hypoglycaemic events. For documentation of hypoglycemic events, the following criteria were taken into consideration:\n\n* Asymptomatic hypoglycemia: the event was not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of \u226470 mg/dL (\u22643.9 mmol/L)\n* Documented symptomatic hypoglycemia with glucose of \u226554 mg/dL and \u226470 mg/dL (\u22653.0 mmol/L and \u22643.9 mmol/L)\n* Documented symptomatic hypoglycemia with glucose of \\<54 mg/dL (\\<3.0 mmol/L): the event was accompanied by typical symptoms of hypoglycemia but in no need for external assistance\n* Severe hypoglycemic episode: the event required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions", "timeFrame": "78 weeks plus 1 week of follow-up"}, {"measure": "Change From Baseline to Week 78 in Lipid Parameters", "description": "Change from baseline to week 78 in lipid parameters (Total cholesterol, High-density lipoprotein (HDL), Low-density lipoprotein (LDL) and Triglyceride)", "timeFrame": "Weeks 1 and 78"}, {"measure": "Clinical Relevant Abnormalities for Physical Examination, Vital Signs, ECG and Laboratory Measurements", "description": "Clinical Relevant Abnormalities for Physical Examination, Vital Signs, ECG and Laboratory Measurements. New abnormal findings or worsening of baseline conditions were reported as treatment related Adverse Events.", "timeFrame": "78 weeks plus 1 week of follow-up"}], "secondaryOutcomes": [{"measure": "Change From Baseline in HbA1c Over Time", "description": "Baseline source: before first intake of active treatment (preceding trial or Open label extension)", "timeFrame": "Weeks 1, 6, 18, 30, 42, 54, 66 and 78"}, {"measure": "Occurence of a Treat-to-target Response (HbA1c < 7.0%)", "description": "Occurence of a treat-to-target response, defined as HbA1c \\< 7.0% over time", "timeFrame": "Weeks 1, 6, 18, 30, 42, 54, 66 and 78"}, {"measure": "Occurrence of a Treat-to-target Response (HbA1c < 6.5%)", "description": "Occurrence of a Treat-to-target Response, defined as HbA1c \\< 6.5% over time", "timeFrame": "Weeks 1, 6, 18, 30, 42, 54, 66 and 78"}, {"measure": "Occurrence of a Relative Efficacy Response", "description": "Occurrence of a Relative Efficacy Response (HbA1c Lowered by at least \\>=0.5% over time)", "timeFrame": "Weeks 1, 6, 18, 30, 42, 54, 66 and 78"}, {"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) Over Time", "description": "Baseline source: before first intake of active treatment (preceding trial or Open label extension)", "timeFrame": "Weeks 1, 6, 18, 30, 42, 54, 66 and 78"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n* patients completing one of double blind phase II trials 1245.9 or 1245.10\n* informed consent\n\nExclusion criteria:\n\n* patients meeting withdrawal criteria of preceding trial\n* significant hepatic impairment\n* significant renal impairment with creatinine clearance \\< 50 ml/min\n* contraindication to Metformin for all patients treated with Metformin\n* premenopausal women that are nursing or pregnant or not practicing acceptable methods of birth control\n* drug or alcohol abuse", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Boehringer Ingelheim", "affiliation": "Boehringer Ingelheim", "role": "STUDY_CHAIR"}], "locations": [{"facility": "1245.24.101001 Boehringer Ingelheim Investigational Site", "city": "Mission Viejo", "state": "California", "country": "United States", "geoPoint": {"lat": 33.60002, "lon": -117.672}}, {"facility": "1245.24.101028 Boehringer Ingelheim Investigational Site", "city": "Spring Valley", "state": "California", "country": "United States", "geoPoint": {"lat": 32.74477, "lon": -116.99892}}, {"facility": "1245.24.101027 Boehringer Ingelheim Investigational Site", "city": "Walnut Creek", "state": "California", "country": "United States", "geoPoint": {"lat": 37.90631, "lon": -122.06496}}, {"facility": "1245.24.101004 Boehringer Ingelheim Investigational Site", "city": "Clearwarter", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.96585, "lon": -82.8001}}, {"facility": "1245.24.101005 Boehringer Ingelheim Investigational Site", "city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "1245.24.101024 Boehringer Ingelheim Investigational Site", "city": "St. Cloud", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.2489, "lon": -81.28118}}, {"facility": "1245.24.101014 Boehringer Ingelheim Investigational Site", "city": "Roswell", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 34.02316, "lon": -84.36159}}, {"facility": "1245.24.101016 Boehringer Ingelheim Investigational Site", "city": "Staten Island", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.56233, "lon": -74.13986}}, {"facility": "1245.24.101006 Boehringer Ingelheim Investigational Site", "city": "Wadsworth", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 41.02561, "lon": -81.72985}}, {"facility": "1245.24.101023 Boehringer Ingelheim Investigational Site", "city": "Norristown", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.1215, "lon": -75.3399}}, {"facility": "1245.24.101015 Boehringer Ingelheim Investigational Site", "city": "Dallas", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "1245.24.101025 Boehringer Ingelheim Investigational Site", "city": "Federal Way", "state": "Washington", "country": "United States", "geoPoint": {"lat": 47.32232, "lon": -122.31262}}, {"facility": "1245.24.431002 Boehringer Ingelheim Investigational Site", "city": "Graz", "country": "Austria", "geoPoint": {"lat": 47.06667, "lon": 15.45}}, {"facility": "1245.24.431001 Boehringer Ingelheim Investigational Site", "city": "Wien", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"facility": "1245.24.431003 Boehringer Ingelheim Investigational Site", "city": "Wien", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"facility": "1245.24.385104 Boehringer Ingelheim Investigational Site", "city": "Karlovac", "country": "Croatia", "geoPoint": {"lat": 45.48941, "lon": 15.54887}}, {"facility": "1245.24.385103 Boehringer Ingelheim Investigational Site", "city": "Krapinske Toplice", "country": "Croatia", "geoPoint": {"lat": 46.09333, "lon": 15.84333}}, {"facility": "1245.24.385106 Boehringer Ingelheim Investigational Site", "city": "Osijek", "country": "Croatia", "geoPoint": {"lat": 45.55111, "lon": 18.69389}}, {"facility": "1245.24.385101 Boehringer Ingelheim Investigational Site", "city": "Zagreb", "country": "Croatia", "geoPoint": {"lat": 45.81444, "lon": 15.97798}}, {"facility": "1245.24.420101 Boehringer Ingelheim Investigational Site", "city": "Breclav", "country": "Czech Republic", "geoPoint": {"lat": 48.75897, "lon": 16.88203}}, {"facility": "1245.24.420103 Boehringer Ingelheim Investigational Site", "city": "Brno", "country": "Czech Republic", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"facility": "1245.24.420105 Boehringer Ingelheim Investigational Site", "city": "Brno", "country": "Czech Republic", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"facility": "1245.24.420102 Boehringer Ingelheim Investigational Site", "city": "Hodonin", "country": "Czech Republic", "geoPoint": {"lat": 48.84893, "lon": 17.13244}}, {"facility": "1245.24.372101 Boehringer Ingelheim Investigational Site", "city": "Tallinn", "country": "Estonia", "geoPoint": {"lat": 59.43696, "lon": 24.75353}}, {"facility": "1245.24.372102 Boehringer Ingelheim Investigational Site", "city": "Tallinn", "country": "Estonia", "geoPoint": {"lat": 59.43696, "lon": 24.75353}}, {"facility": "1245.24.372103 Boehringer Ingelheim Investigational Site", "city": "Tallinn", "country": "Estonia", "geoPoint": {"lat": 59.43696, "lon": 24.75353}}, {"facility": "1245.24.372104 Boehringer Ingelheim Investigational Site", "city": "Tallinn", "country": "Estonia", "geoPoint": {"lat": 59.43696, "lon": 24.75353}}, {"facility": "1245.24.372105 Boehringer Ingelheim Investigational Site", "city": "Tartu", "country": "Estonia", "geoPoint": {"lat": 58.38062, "lon": 26.72509}}, {"facility": "1245.24.581006 Boehringer Ingelheim Investigational Site", "city": "Kerava", "country": "Finland", "geoPoint": {"lat": 60.40338, "lon": 25.105}}, {"facility": "1245.24.581003 Boehringer Ingelheim Investigational Site", "city": "Oulu", "country": "Finland", "geoPoint": {"lat": 65.01236, "lon": 25.46816}}, {"facility": "1245.24.581004 Boehringer Ingelheim Investigational Site", "city": "Tampere", "country": "Finland", "geoPoint": {"lat": 61.49911, "lon": 23.78712}}, {"facility": "1245.24.581001 Boehringer Ingelheim Investigational Site", "city": "Turku", "country": "Finland", "geoPoint": {"lat": 60.45148, "lon": 22.26869}}, {"facility": "1245.24.3302A Boehringer Ingelheim Investigational Site", "city": "Bondy Cedex", "country": "France", "geoPoint": {"lat": 48.9018, "lon": 2.48931}}, {"facility": "1245.24.3302B Boehringer Ingelheim Investigational Site", "city": "Bondy Cedex", "country": "France", "geoPoint": {"lat": 48.9018, "lon": 2.48931}}, {"facility": "1245.24.3310A Boehringer Ingelheim Investigational Site", "city": "Caen Cedex 5", "country": "France", "geoPoint": {"lat": 49.18585, "lon": -0.35912}}, {"facility": "1245.24.3310C Boehringer Ingelheim Investigational Site", "city": "Caen Cedex 5", "country": "France", "geoPoint": {"lat": 49.18585, "lon": -0.35912}}, {"facility": "1245.24.3301A Boehringer Ingelheim Investigational Site", "city": "Corbeil Essonnes", "country": "France", "geoPoint": {"lat": 48.60603, "lon": 2.48757}}, {"facility": "1245.24.3303A Boehringer Ingelheim Investigational Site", "city": "La Rochelle Cedex 1", "country": "France", "geoPoint": {"lat": 46.16667, "lon": -1.15}}, {"facility": "1245.24.3303B Boehringer Ingelheim Investigational Site", "city": "La Rochelle Cedex 1", "country": "France", "geoPoint": {"lat": 46.16667, "lon": -1.15}}, {"facility": "1245.24.3309A Boehringer Ingelheim Investigational Site", "city": "Nanterre Cedex", "country": "France", "geoPoint": {"lat": 48.89198, "lon": 2.20675}}, {"facility": "1245.24.3306A Boehringer Ingelheim Investigational Site", "city": "Narbonne Cedex", "country": "France", "geoPoint": {"lat": 43.18396, "lon": 3.00141}}, {"facility": "1245.24.3304A Boehringer Ingelheim Investigational Site", "city": "Reims Cedex", "country": "France", "geoPoint": {"lat": 49.25, "lon": 4.03333}}, {"facility": "1245.24.3311B Boehringer Ingelheim Investigational Site", "city": "Saint Mand\u00e9", "country": "France", "geoPoint": {"lat": 48.83864, "lon": 2.41579}}, {"facility": "1245.24.3305A Boehringer Ingelheim Investigational Site", "city": "Valenciennes", "country": "France", "geoPoint": {"lat": 50.35, "lon": 3.53333}}, {"facility": "1245.24.3305B Boehringer Ingelheim Investigational Site", "city": "Valenciennes", "country": "France", "geoPoint": {"lat": 50.35, "lon": 3.53333}}, {"facility": "1245.24.491011 Boehringer Ingelheim Investigational Site", "city": "Aschaffenburg", "country": "Germany", "geoPoint": {"lat": 49.97704, "lon": 9.15214}}, {"facility": "1245.24.491007 Boehringer Ingelheim Investigational Site", "city": "Frankfurt am Main", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "1245.24.491004 Boehringer Ingelheim Investigational Site", "city": "Hamburg", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "1245.24.491005 Boehringer Ingelheim Investigational Site", "city": "Hamburg", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "1245.24.491002 Boehringer Ingelheim Investigational Site", "city": "Melsungen", "country": "Germany", "geoPoint": {"lat": 51.13029, "lon": 9.55236}}, {"facility": "1245.24.491012 Boehringer Ingelheim Investigational Site", "city": "N\u00fcrnberg", "country": "Germany", "geoPoint": {"lat": 49.45421, "lon": 11.07752}}, {"facility": "1245.24.491008 Boehringer Ingelheim Investigational Site", "city": "Rehlingen-Siersburg", "country": "Germany", "geoPoint": {"lat": 49.36023, "lon": 6.66731}}, {"facility": "1245.24.491003 Boehringer Ingelheim Investigational Site", "city": "St. Ingbert/Oberw\u00fcrzbach", "country": "Germany"}, {"facility": "1245.24.491010 Boehringer Ingelheim Investigational Site", "city": "Sulzbach-Rosenberg", "country": "Germany", "geoPoint": {"lat": 49.50126, "lon": 11.74598}}, {"facility": "1245.24.361001 Boehringer Ingelheim Investigational Site", "city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "1245.24.361003 Boehringer Ingelheim Investigational Site", "city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "1245.24.361004 Boehringer Ingelheim Investigational Site", "city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "1245.24.361005 Boehringer Ingelheim Investigational Site", "city": "Gyor", "country": "Hungary", "geoPoint": {"lat": 47.68333, "lon": 17.63512}}, {"facility": "1245.24.361002 Boehringer Ingelheim Investigational Site", "city": "Szombathely", "country": "Hungary", "geoPoint": {"lat": 47.23088, "lon": 16.62155}}, {"facility": "1245.24.391006 Boehringer Ingelheim Investigational Site", "city": "Genova", "country": "Italy", "geoPoint": {"lat": 44.40478, "lon": 8.94438}}, {"facility": "1245.24.391003 Boehringer Ingelheim Investigational Site", "city": "Pisa", "country": "Italy", "geoPoint": {"lat": 43.70853, "lon": 10.4036}}, {"facility": "1245.24.391005 Boehringer Ingelheim Investigational Site", "city": "Treviso", "country": "Italy", "geoPoint": {"lat": 45.66673, "lon": 12.2416}}, {"facility": "1245.24.821006 Boehringer Ingelheim Investigational Site", "city": "Goyang", "country": "Korea, Republic of", "geoPoint": {"lat": 37.65639, "lon": 126.835}}, {"facility": "1245.24.821008 Boehringer Ingelheim Investigational Site", "city": "Goyang", "country": "Korea, Republic of", "geoPoint": {"lat": 37.65639, "lon": 126.835}}, {"facility": "1245.24.821007 Boehringer Ingelheim Investigational Site", "city": "Incheon", "country": "Korea, Republic of", "geoPoint": {"lat": 37.45646, "lon": 126.70515}}, {"facility": "1245.24.821002 Boehringer Ingelheim Investigational Site", "city": "Pucheon", "country": "Korea, Republic of"}, {"facility": "1245.24.821001 Boehringer Ingelheim Investigational Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "1245.24.821004 Boehringer Ingelheim Investigational Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "1245.24.821009 Boehringer Ingelheim Investigational Site", "city": "Suwon", "country": "Korea, Republic of", "geoPoint": {"lat": 37.29111, "lon": 127.00889}}, {"facility": "1245.24.821003 Boehringer Ingelheim Investigational Site", "city": "Uijeongbu", "country": "Korea, Republic of", "geoPoint": {"lat": 37.7415, "lon": 127.0474}}, {"facility": "1245.24.371101 Boehringer Ingelheim Investigational Site", "city": "Daugavpils", "country": "Latvia", "geoPoint": {"lat": 55.88333, "lon": 26.53333}}, {"facility": "1245.24.371105 Boehringer Ingelheim Investigational Site", "city": "Kuldiga", "country": "Latvia", "geoPoint": {"lat": 56.97399, "lon": 21.95721}}, {"facility": "1245.24.371106 Boehringer Ingelheim Investigational Site", "city": "Ogre", "country": "Latvia", "geoPoint": {"lat": 56.8162, "lon": 24.61401}}, {"facility": "1245.24.371103 Boehringer Ingelheim Investigational Site", "city": "Riga", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "1245.24.371107 Boehringer Ingelheim Investigational Site", "city": "Riga", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "1245.24.371102 Boehringer Ingelheim Investigational Site", "city": "Talsi", "country": "Latvia", "geoPoint": {"lat": 57.24562, "lon": 22.58137}}, {"facility": "1245.24.371104 Boehringer Ingelheim Investigational Site", "city": "Valmiera", "country": "Latvia", "geoPoint": {"lat": 57.54108, "lon": 25.42751}}, {"facility": "1245.24.370102 Boehringer Ingelheim Investigational Site", "city": "Klaipeda", "country": "Lithuania", "geoPoint": {"lat": 55.70888, "lon": 21.14311}}, {"facility": "1245.24.370101 Boehringer Ingelheim Investigational Site", "city": "Vilnius", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "1245.24.471003 Boehringer Ingelheim Investigational Site", "city": "Hamar", "country": "Norway", "geoPoint": {"lat": 60.7945, "lon": 11.06798}}, {"facility": "1245.24.471005 Boehringer Ingelheim Investigational Site", "city": "Oslo", "country": "Norway", "geoPoint": {"lat": 59.91273, "lon": 10.74609}}, {"facility": "1245.24.471001 Boehringer Ingelheim Investigational Site", "city": "Stavanger", "country": "Norway", "geoPoint": {"lat": 58.97005, "lon": 5.73332}}, {"facility": "1245.24.471004 Boehringer Ingelheim Investigational Site", "city": "\u00c5lesund", "country": "Norway", "geoPoint": {"lat": 62.47225, "lon": 6.15492}}, {"facility": "1245.24.401005 Boehringer Ingelheim Investigational Site", "city": "Alba Iulia", "country": "Romania", "geoPoint": {"lat": 46.06667, "lon": 23.58333}}, {"facility": "1245.24.401006 Boehringer Ingelheim Investigational Site", "city": "Baia Mare Maramures", "country": "Romania"}, {"facility": "1245.24.401002 Boehringer Ingelheim Investigational Site", "city": "Brasov", "country": "Romania", "geoPoint": {"lat": 45.64861, "lon": 25.60613}}, {"facility": "1245.24.401001 Boehringer Ingelheim Investigational Site", "city": "Bucharest", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "1245.24.401008 Boehringer Ingelheim Investigational Site", "city": "Bucharest", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "1245.24.401003 Boehringer Ingelheim Investigational Site", "city": "Galati", "country": "Romania", "geoPoint": {"lat": 45.45, "lon": 28.05}}, {"facility": "1245.24.401007 Boehringer Ingelheim Investigational Site", "city": "Satu Mare", "country": "Romania", "geoPoint": {"lat": 47.79926, "lon": 22.86255}}, {"facility": "1245.24.401004 Boehringer Ingelheim Investigational Site", "city": "Targu-Mures", "country": "Romania", "geoPoint": {"lat": 46.54245, "lon": 24.55747}}, {"facility": "1245.24.701001 Boehringer Ingelheim Investigational Site", "city": "Ekaterinburg", "country": "Russian Federation", "geoPoint": {"lat": 56.8519, "lon": 60.6122}}, {"facility": "1245.24.701002 Boehringer Ingelheim Investigational Site", "city": "Kazan", "country": "Russian Federation", "geoPoint": {"lat": 55.78874, "lon": 49.12214}}, {"facility": "1245.24.701008 Boehringer Ingelheim Investigational Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "1245.24.701009 Boehringer Ingelheim Investigational Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "1245.24.701010 Boehringer Ingelheim Investigational Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "1245.24.701004 Boehringer Ingelheim Investigational Site", "city": "Petrozavodsk", "country": "Russian Federation", "geoPoint": {"lat": 61.78491, "lon": 34.34691}}, {"facility": "1245.24.701014 Boehringer Ingelheim Investigational Site", "city": "Saratov", "country": "Russian Federation", "geoPoint": {"lat": 51.54056, "lon": 46.00861}}, {"facility": "1245.24.701005 Boehringer Ingelheim Investigational Site", "city": "Smolensk", "country": "Russian Federation", "geoPoint": {"lat": 54.7818, "lon": 32.0401}}, {"facility": "1245.24.701012 Boehringer Ingelheim Investigational Site", "city": "St. Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "1245.24.701013 Boehringer Ingelheim Investigational Site", "city": "St. Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "1245.24.701006 Boehringer Ingelheim Investigational Site", "city": "Yaroslavl", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}, {"facility": "1245.24.701007 Boehringer Ingelheim Investigational Site", "city": "Yaroslavl", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}, {"facility": "1245.24.421102 Boehringer Ingelheim Investigational Site", "city": "Bratislava", "country": "Slovakia", "geoPoint": {"lat": 48.14816, "lon": 17.10674}}, {"facility": "1245.24.421107 Boehringer Ingelheim Investigational Site", "city": "Bratislava", "country": "Slovakia", "geoPoint": {"lat": 48.14816, "lon": 17.10674}}, {"facility": "1245.24.421103 Boehringer Ingelheim Investigational Site", "city": "Lucenec", "country": "Slovakia", "geoPoint": {"lat": 48.33249, "lon": 19.66708}}, {"facility": "1245.24.421105 Boehringer Ingelheim Investigational Site", "city": "Nitra", "country": "Slovakia", "geoPoint": {"lat": 48.30763, "lon": 18.08453}}, {"facility": "1245.24.421106 Boehringer Ingelheim Investigational Site", "city": "Nitra", "country": "Slovakia", "geoPoint": {"lat": 48.30763, "lon": 18.08453}}, {"facility": "1245.24.421104 Boehringer Ingelheim Investigational Site", "city": "Nove Mesto Nad Vahom", "country": "Slovakia", "geoPoint": {"lat": 48.75763, "lon": 17.8309}}, {"facility": "1245.24.421108 Boehringer Ingelheim Investigational Site", "city": "Presov", "country": "Slovakia", "geoPoint": {"lat": 48.99839, "lon": 21.23393}}, {"facility": "1245.24.421101 Boehringer Ingelheim Investigational Site", "city": "Prievidza", "country": "Slovakia", "geoPoint": {"lat": 48.77446, "lon": 18.6275}}, {"facility": "1245.24.341002 Boehringer Ingelheim Investigational Site", "city": "Barcelona", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "1245.24.341001 Boehringer Ingelheim Investigational Site", "city": "Girona", "country": "Spain", "geoPoint": {"lat": 41.98311, "lon": 2.82493}}, {"facility": "1245.24.341010 Boehringer Ingelheim Investigational Site", "city": "L'Hospitalet de Llobregat (Barcelona)", "country": "Spain"}, {"facility": "1245.24.341004 Boehringer Ingelheim Investigational Site", "city": "M\u00e1laga", "country": "Spain", "geoPoint": {"lat": 36.72016, "lon": -4.42034}}, {"facility": "1245.24.341005 Boehringer Ingelheim Investigational Site", "city": "Palma Mallorca", "country": "Spain", "geoPoint": {"lat": 39.56939, "lon": 2.65024}}, {"facility": "1245.24.341006 Boehringer Ingelheim Investigational Site", "city": "Palma Mallorca", "country": "Spain", "geoPoint": {"lat": 39.56939, "lon": 2.65024}}, {"facility": "1245.24.341008 Boehringer Ingelheim Investigational Site", "city": "Santander", "country": "Spain", "geoPoint": {"lat": 43.46472, "lon": -3.80444}}, {"facility": "1245.24.461004 Boehringer Ingelheim Investigational Site", "city": "H\u00e4rn\u00f6sand", "country": "Sweden", "geoPoint": {"lat": 62.63228, "lon": 17.93794}}, {"facility": "1245.24.461005 Boehringer Ingelheim Investigational Site", "city": "Lund", "country": "Sweden", "geoPoint": {"lat": 55.70584, "lon": 13.19321}}, {"facility": "1245.24.461001 Boehringer Ingelheim Investigational Site", "city": "Stockholm", "country": "Sweden", "geoPoint": {"lat": 59.33258, "lon": 18.0649}}, {"facility": "1245.24.886105 Boehringer Ingelheim Investigational Site", "city": "Changhua", "country": "Taiwan", "geoPoint": {"lat": 24.07327, "lon": 120.56276}}, {"facility": "1245.24.886107 Boehringer Ingelheim Investigational Site", "city": "Kaohsiung", "country": "Taiwan", "geoPoint": {"lat": 22.61626, "lon": 120.31333}}, {"facility": "1245.24.886104 Boehringer Ingelheim Investigational Site", "city": "Taichun", "country": "Taiwan", "geoPoint": {"lat": 24.1469, "lon": 120.6839}}, {"facility": "1245.24.886106 Boehringer Ingelheim Investigational Site", "city": "Tainan", "country": "Taiwan", "geoPoint": {"lat": 22.99083, "lon": 120.21333}}, {"facility": "1245.24.886101 Boehringer Ingelheim Investigational Site", "city": "Taipei", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "1245.24.886103 Boehringer Ingelheim Investigational Site", "city": "Taipei", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "1245.24.886102 Boehringer Ingelheim Investigational Site", "city": "Taoyuan", "country": "Taiwan", "geoPoint": {"lat": 24.95233, "lon": 121.20193}}, {"facility": "1245.24.381007 Boehringer Ingelheim Investigational Site", "city": "Dnepropetrovsk", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "1245.24.381010 Boehringer Ingelheim Investigational Site", "city": "Kharkiv", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "1245.24.381003 Boehringer Ingelheim Investigational Site", "city": "Kharkov", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "1245.24.381009 Boehringer Ingelheim Investigational Site", "city": "Kharkov", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "1245.24.381008 Boehringer Ingelheim Investigational Site", "city": "Kiev", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "1245.24.381002 Boehringer Ingelheim Investigational Site", "city": "Odessa", "country": "Ukraine", "geoPoint": {"lat": 46.47747, "lon": 30.73262}}, {"facility": "1245.24.381006 Boehringer Ingelheim Investigational Site", "city": "Vinnitsa", "country": "Ukraine", "geoPoint": {"lat": 49.84639, "lon": 37.71861}}, {"facility": "1245.24.381001 Boehringer Ingelheim Investigational Site", "city": "Vinnytsya", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}, {"facility": "1245.24.381005 Boehringer Ingelheim Investigational Site", "city": "Vinnytsya", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}]}, "referencesModule": {"references": [{"pmid": "24186878", "type": "DERIVED", "citation": "Ferrannini E, Berk A, Hantel S, Pinnetti S, Hach T, Woerle HJ, Broedl UC. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013 Dec;36(12):4015-21. doi: 10.2337/dc13-0663. Epub 2013 Nov 1."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Patients from the preceding empagliflozin 10 and 25 mg groups continued to take the same doses. Patients on placebo and other empagliflozin doses were re-randomised to one of the empagliflozin treatments. Patients on metformin monotherapy or sitagliptin added-on to metformin in the preceding trials continued their open label treatments.", "recruitmentDetails": "This was an open label extension trial of the blinded 12-week dose-finding studies NCT00789035 and NCT00749190.", "groups": [{"id": "FG000", "title": "Empagliflozin 10 mg", "description": "Patients receive 10 mg Empagliflozin in tablets once daily."}, {"id": "FG001", "title": "Empagliflozin 25 mg", "description": "Patients receive 25 mg Empagliflozin in tablets once daily."}, {"id": "FG002", "title": "Metformin", "description": "Patients receive between 1000 and 2000 mg Metformin daily as monotherapy. Patients on metformin as active comparator (from trial NCT00789035) were to take their medication according to the instruction of their investigator, continuing the maximum tolerated dose determined in the preceding trial."}, {"id": "FG003", "title": "Empagliflozin 10 mg + Metformin", "description": "Patients receive 10 mg Empagliflozin in tablets once daily added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}, {"id": "FG004", "title": "Empagliflozin 25 mg + Metformin", "description": "Patients receive 25 mg Empagliflozin in tablets once daily added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}, {"id": "FG005", "title": "Sitaglipin + Metformin", "description": "Patients receive 100 mg Sitagliptin once daily in tablets added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "106"}, {"groupId": "FG001", "numSubjects": "109"}, {"groupId": "FG002", "numSubjects": "56"}, {"groupId": "FG003", "numSubjects": "166"}, {"groupId": "FG004", "numSubjects": "166"}, {"groupId": "FG005", "numSubjects": "56"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "92"}, {"groupId": "FG001", "numSubjects": "104"}, {"groupId": "FG002", "numSubjects": "51"}, {"groupId": "FG003", "numSubjects": "157"}, {"groupId": "FG004", "numSubjects": "152"}, {"groupId": "FG005", "numSubjects": "51"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "9"}, {"groupId": "FG004", "numSubjects": "14"}, {"groupId": "FG005", "numSubjects": "5"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "4"}, {"groupId": "FG004", "numSubjects": "10"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}]}, {"type": "Not compliant with the protocol", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Refused to continue medication", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Other reason not defined above", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Treated set including all patients treated with at least 1 dose of study drug.", "groups": [{"id": "BG000", "title": "Empagliflozin 10 mg", "description": "Patients receive 10 mg Empagliflozin in tablets once daily."}, {"id": "BG001", "title": "Empagliflozin 25 mg", "description": "Patients receive 25 mg Empagliflozin in tablets once daily."}, {"id": "BG002", "title": "Metformin", "description": "Patients receive between 1000 and 2000 mg Metformin daily as monotherapy. Patients on metformin as active comparator (from trial NCT00789035) were to take their medication according to the instruction of their investigator, continuing the maximum tolerated dose determined in the preceding trial."}, {"id": "BG003", "title": "Empagliflozin 10 mg + Metformin", "description": "Patients receive 10 mg Empagliflozin in tablets once daily added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}, {"id": "BG004", "title": "Empagliflozin 25 mg + Metformin", "description": "Patients receive 25 mg Empagliflozin in tablets once daily added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}, {"id": "BG005", "title": "Sitaglipin + Metformin", "description": "Patients receive 100 mg Sitagliptin once daily in tablets added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}, {"id": "BG006", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "106"}, {"groupId": "BG001", "value": "109"}, {"groupId": "BG002", "value": "56"}, {"groupId": "BG003", "value": "166"}, {"groupId": "BG004", "value": "166"}, {"groupId": "BG005", "value": "56"}, {"groupId": "BG006", "value": "659"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58.3", "spread": "8.5"}, {"groupId": "BG001", "value": "58.5", "spread": "10.0"}, {"groupId": "BG002", "value": "56.8", "spread": "8.9"}, {"groupId": "BG003", "value": "58.4", "spread": "8.3"}, {"groupId": "BG004", "value": "59.9", "spread": "7.8"}, {"groupId": "BG005", "value": "58.3", "spread": "10.5"}, {"groupId": "BG006", "value": "58.6", "spread": "8.8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "57"}, {"groupId": "BG001", "value": "52"}, {"groupId": "BG002", "value": "28"}, {"groupId": "BG003", "value": "83"}, {"groupId": "BG004", "value": "78"}, {"groupId": "BG005", "value": "27"}, {"groupId": "BG006", "value": "325"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "49"}, {"groupId": "BG001", "value": "57"}, {"groupId": "BG002", "value": "28"}, {"groupId": "BG003", "value": "83"}, {"groupId": "BG004", "value": "88"}, {"groupId": "BG005", "value": "29"}, {"groupId": "BG006", "value": "334"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Hypoglycaemic Events", "description": "Investigator defined Hypoglycaemic events. For documentation of hypoglycemic events, the following criteria were taken into consideration:\n\n* Asymptomatic hypoglycemia: the event was not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of \u226470 mg/dL (\u22643.9 mmol/L)\n* Documented symptomatic hypoglycemia with glucose of \u226554 mg/dL and \u226470 mg/dL (\u22653.0 mmol/L and \u22643.9 mmol/L)\n* Documented symptomatic hypoglycemia with glucose of \\<54 mg/dL (\\<3.0 mmol/L): the event was accompanied by typical symptoms of hypoglycemia but in no need for external assistance\n* Severe hypoglycemic episode: the event required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions", "populationDescription": "Treated set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "78 weeks plus 1 week of follow-up", "groups": [{"id": "OG000", "title": "Empagliflozin 10 mg", "description": "Patients receive 10 mg Empagliflozin in tablets once daily."}, {"id": "OG001", "title": "Empagliflozin 25 mg", "description": "Patients receive 25 mg Empagliflozin in tablets once daily."}, {"id": "OG002", "title": "Metformin", "description": "Patients receive between 1000 and 2000 mg Metformin daily as monotherapy. Patients on metformin as active comparator (from trial NCT00789035) were to take their medication according to the instruction of their investigator, continuing the maximum tolerated dose determined in the preceding trial."}, {"id": "OG003", "title": "Empagliflozin 10 mg + Metformin", "description": "Patients receive 10 mg Empagliflozin in tablets once daily added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}, {"id": "OG004", "title": "Empagliflozin 25 mg + Metformin", "description": "Patients receive 25 mg Empagliflozin in tablets once daily added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}, {"id": "OG005", "title": "Sitaglipin + Metformin", "description": "Patients receive 100 mg Sitagliptin once daily in tablets added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "109"}, {"groupId": "OG002", "value": "56"}, {"groupId": "OG003", "value": "166"}, {"groupId": "OG004", "value": "166"}, {"groupId": "OG005", "value": "56"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.9"}, {"groupId": "OG001", "value": "1.8"}, {"groupId": "OG002", "value": "7.1"}, {"groupId": "OG003", "value": "2.4"}, {"groupId": "OG004", "value": "3.6"}, {"groupId": "OG005", "value": "5.4"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline to Week 78 in Lipid Parameters", "description": "Change from baseline to week 78 in lipid parameters (Total cholesterol, High-density lipoprotein (HDL), Low-density lipoprotein (LDL) and Triglyceride)", "populationDescription": "Treated set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Weeks 1 and 78", "groups": [{"id": "OG000", "title": "Empagliflozin 10 mg", "description": "Patients receive 10 mg Empagliflozin in tablets once daily."}, {"id": "OG001", "title": "Empagliflozin 25 mg", "description": "Patients receive 25 mg Empagliflozin in tablets once daily."}, {"id": "OG002", "title": "Metformin", "description": "Patients receive between 1000 and 2000 mg Metformin daily as monotherapy. Patients on metformin as active comparator (from trial NCT00789035) were to take their medication according to the instruction of their investigator, continuing the maximum tolerated dose determined in the preceding trial."}, {"id": "OG003", "title": "Empagliflozin 10 mg + Metformin", "description": "Patients receive 10 mg Empagliflozin in tablets once daily added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}, {"id": "OG004", "title": "Empagliflozin 25 mg + Metformin", "description": "Patients receive 25 mg Empagliflozin in tablets once daily added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}, {"id": "OG005", "title": "Sitaglipin + Metformin", "description": "Patients receive 100 mg Sitagliptin once daily in tablets added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "109"}, {"groupId": "OG002", "value": "56"}, {"groupId": "OG003", "value": "164"}, {"groupId": "OG004", "value": "162"}, {"groupId": "OG005", "value": "56"}]}], "classes": [{"title": "Total Cholesterol", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.13", "spread": "1.17"}, {"groupId": "OG001", "value": "0.09", "spread": "0.88"}, {"groupId": "OG002", "value": "-0.24", "spread": "0.77"}, {"groupId": "OG003", "value": "0.19", "spread": "0.81"}, {"groupId": "OG004", "value": "0.13", "spread": "0.75"}, {"groupId": "OG005", "value": "-0.05", "spread": "0.91"}]}]}, {"title": "HDL", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.08", "spread": "0.11"}, {"groupId": "OG001", "value": "0.07", "spread": "0.10"}, {"groupId": "OG002", "value": "0.06", "spread": "0.10"}, {"groupId": "OG003", "value": "0.06", "spread": "0.09"}, {"groupId": "OG004", "value": "0.07", "spread": "0.10"}, {"groupId": "OG005", "value": "0.03", "spread": "0.08"}]}]}, {"title": "LDL (N=102, 108, 52, 161, 159, 55)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.02", "spread": "0.83"}, {"groupId": "OG001", "value": "0.05", "spread": "0.83"}, {"groupId": "OG002", "value": "-0.13", "spread": "0.74"}, {"groupId": "OG003", "value": "0.13", "spread": "0.71"}, {"groupId": "OG004", "value": "0.07", "spread": "0.69"}, {"groupId": "OG005", "value": "0.00", "spread": "0.79"}]}]}, {"title": "Triglyceride", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5", "spread": "2.3"}, {"groupId": "OG001", "value": "-0.0", "spread": "0.6"}, {"groupId": "OG002", "value": "-0.5", "spread": "1.2"}, {"groupId": "OG003", "value": "0.1", "spread": "0.9"}, {"groupId": "OG004", "value": "-0.1", "spread": "0.8"}, {"groupId": "OG005", "value": "-0.2", "spread": "0.9"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in HbA1c Over Time", "description": "Baseline source: before first intake of active treatment (preceding trial or Open label extension)", "populationDescription": "Treated set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of HbA1c", "timeFrame": "Weeks 1, 6, 18, 30, 42, 54, 66 and 78", "groups": [{"id": "OG000", "title": "Empagliflozin 10 mg", "description": "Patients receive 10 mg Empagliflozin in tablets once daily."}, {"id": "OG001", "title": "Empagliflozin 25 mg", "description": "Patients receive 25 mg Empagliflozin in tablets once daily."}, {"id": "OG002", "title": "Metformin", "description": "Patients receive between 1000 and 2000 mg Metformin daily as monotherapy. Patients on metformin as active comparator (from trial NCT00789035) were to take their medication according to the instruction of their investigator, continuing the maximum tolerated dose determined in the preceding trial."}, {"id": "OG003", "title": "Empagliflozin 10 mg + Metformin", "description": "Patients receive 10 mg Empagliflozin in tablets once daily added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}, {"id": "OG004", "title": "Empagliflozin 25 mg + Metformin", "description": "Patients receive 25 mg Empagliflozin in tablets once daily added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}, {"id": "OG005", "title": "Sitaglipin + Metformin", "description": "Patients receive 100 mg Sitagliptin once daily in tablets added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "109"}, {"groupId": "OG002", "value": "56"}, {"groupId": "OG003", "value": "166"}, {"groupId": "OG004", "value": "166"}, {"groupId": "OG005", "value": "56"}]}], "classes": [{"title": "Week 6 (N=104, 108, 55, 162, 163, 54)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.40", "spread": "0.77"}, {"groupId": "OG001", "value": "-0.57", "spread": "0.81"}, {"groupId": "OG002", "value": "-1.03", "spread": "0.76"}, {"groupId": "OG003", "value": "-0.36", "spread": "0.67"}, {"groupId": "OG004", "value": "-0.55", "spread": "0.60"}, {"groupId": "OG005", "value": "-0.75", "spread": "0.80"}]}]}, {"title": "Week 18 (N=93, 105, 53, 149, 157, 48)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.58", "spread": "0.75"}, {"groupId": "OG001", "value": "-0.72", "spread": "0.88"}, {"groupId": "OG002", "value": "-0.92", "spread": "0.91"}, {"groupId": "OG003", "value": "-0.51", "spread": "0.68"}, {"groupId": "OG004", "value": "-0.70", "spread": "0.68"}, {"groupId": "OG005", "value": "-0.79", "spread": "0.84"}]}]}, {"title": "Week 30 (N=93, 99, 50, 140, 151, 45)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.47", "spread": "0.85"}, {"groupId": "OG001", "value": "-0.61", "spread": "0.90"}, {"groupId": "OG002", "value": "-0.95", "spread": "0.82"}, {"groupId": "OG003", "value": "-0.58", "spread": "0.69"}, {"groupId": "OG004", "value": "-0.76", "spread": "0.70"}, {"groupId": "OG005", "value": "-0.68", "spread": "0.82"}]}]}, {"title": "Week 42 (N=85, 93, 46, 132, 140, 44)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.59", "spread": "0.87"}, {"groupId": "OG001", "value": "-0.74", "spread": "0.98"}, {"groupId": "OG002", "value": "-1.10", "spread": "0.80"}, {"groupId": "OG003", "value": "-0.65", "spread": "0.72"}, {"groupId": "OG004", "value": "-0.79", "spread": "0.76"}, {"groupId": "OG005", "value": "-0.51", "spread": "1.03"}]}]}, {"title": "Week 54 (N=78, 85, 44, 128, 136, 41)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.66", "spread": "0.83"}, {"groupId": "OG001", "value": "-0.71", "spread": "0.87"}, {"groupId": "OG002", "value": "-1.13", "spread": "0.89"}, {"groupId": "OG003", "value": "-0.62", "spread": "0.76"}, {"groupId": "OG004", "value": "-0.75", "spread": "0.73"}, {"groupId": "OG005", "value": "-0.79", "spread": "0.79"}]}]}, {"title": "Week 66 (N=80, 87, 43, 120, 127, 39)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.55", "spread": "0.80"}, {"groupId": "OG001", "value": "-0.71", "spread": "1.01"}, {"groupId": "OG002", "value": "-1.04", "spread": "0.79"}, {"groupId": "OG003", "value": "-0.59", "spread": "0.79"}, {"groupId": "OG004", "value": "-0.73", "spread": "0.77"}, {"groupId": "OG005", "value": "-0.78", "spread": "0.90"}]}]}, {"title": "Week 78 (N=72, 84, 42, 115, 121, 38)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.50", "spread": "0.77"}, {"groupId": "OG001", "value": "-0.55", "spread": "0.90"}, {"groupId": "OG002", "value": "-0.80", "spread": "0.88"}, {"groupId": "OG003", "value": "-0.56", "spread": "0.80"}, {"groupId": "OG004", "value": "-0.71", "spread": "0.81"}, {"groupId": "OG005", "value": "-0.66", "spread": "0.99"}]}]}]}, {"type": "SECONDARY", "title": "Occurence of a Treat-to-target Response (HbA1c < 7.0%)", "description": "Occurence of a treat-to-target response, defined as HbA1c \\< 7.0% over time", "populationDescription": "Treated set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Weeks 1, 6, 18, 30, 42, 54, 66 and 78", "groups": [{"id": "OG000", "title": "Empagliflozin 10 mg", "description": "Patients receive 10 mg Empagliflozin in tablets once daily."}, {"id": "OG001", "title": "Empagliflozin 25 mg", "description": "Patients receive 25 mg Empagliflozin in tablets once daily."}, {"id": "OG002", "title": "Metformin", "description": "Patients receive between 1000 and 2000 mg Metformin daily as monotherapy. Patients on metformin as active comparator (from trial NCT00789035) were to take their medication according to the instruction of their investigator, continuing the maximum tolerated dose determined in the preceding trial."}, {"id": "OG003", "title": "Empagliflozin 10 mg + Metformin", "description": "Patients receive 10 mg Empagliflozin in tablets once daily added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}, {"id": "OG004", "title": "Empagliflozin 25 mg + Metformin", "description": "Patients receive 25 mg Empagliflozin in tablets once daily added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}, {"id": "OG005", "title": "Sitaglipin + Metformin", "description": "Patients receive 100 mg Sitagliptin once daily in tablets added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "109"}, {"groupId": "OG002", "value": "56"}, {"groupId": "OG003", "value": "166"}, {"groupId": "OG004", "value": "166"}, {"groupId": "OG005", "value": "56"}]}], "classes": [{"title": "Week 6 (N=104, 108, 55, 162, 163, 54)", "categories": [{"measurements": [{"groupId": "OG000", "value": "26.9"}, {"groupId": "OG001", "value": "25.0"}, {"groupId": "OG002", "value": "45.5"}, {"groupId": "OG003", "value": "24.1"}, {"groupId": "OG004", "value": "25.2"}, {"groupId": "OG005", "value": "35.2"}]}]}, {"title": "Week 18 (N=93, 105, 53, 149, 157, 48)", "categories": [{"measurements": [{"groupId": "OG000", "value": "33.3"}, {"groupId": "OG001", "value": "33.3"}, {"groupId": "OG002", "value": "45.3"}, {"groupId": "OG003", "value": "31.5"}, {"groupId": "OG004", "value": "37.6"}, {"groupId": "OG005", "value": "35.4"}]}]}, {"title": "Week 30 (N=93, 99, 50, 140, 151, 45)", "categories": [{"measurements": [{"groupId": "OG000", "value": "34.4"}, {"groupId": "OG001", "value": "29.3"}, {"groupId": "OG002", "value": "42.0"}, {"groupId": "OG003", "value": "28.6"}, {"groupId": "OG004", "value": "45.7"}, {"groupId": "OG005", "value": "28.9"}]}]}, {"title": "Week 42 (N=85, 93, 46, 132, 140, 44)", "categories": [{"measurements": [{"groupId": "OG000", "value": "41.2"}, {"groupId": "OG001", "value": "40.9"}, {"groupId": "OG002", "value": "52.2"}, {"groupId": "OG003", "value": "39.4"}, {"groupId": "OG004", "value": "47.1"}, {"groupId": "OG005", "value": "25.0"}]}]}, {"title": "Week 54 (N=78, 85, 44, 128, 136, 41)", "categories": [{"measurements": [{"groupId": "OG000", "value": "43.6"}, {"groupId": "OG001", "value": "32.9"}, {"groupId": "OG002", "value": "56.8"}, {"groupId": "OG003", "value": "35.9"}, {"groupId": "OG004", "value": "47.8"}, {"groupId": "OG005", "value": "29.3"}]}]}, {"title": "Week 66 (N=80, 87, 43, 120, 127, 39)", "categories": [{"measurements": [{"groupId": "OG000", "value": "31.3"}, {"groupId": "OG001", "value": "39.1"}, {"groupId": "OG002", "value": "44.2"}, {"groupId": "OG003", "value": "35.8"}, {"groupId": "OG004", "value": "48.0"}, {"groupId": "OG005", "value": "38.5"}]}]}, {"title": "Week 78 (N=72, 84, 42, 115, 121, 38)", "categories": [{"measurements": [{"groupId": "OG000", "value": "31.9"}, {"groupId": "OG001", "value": "32.1"}, {"groupId": "OG002", "value": "31.0"}, {"groupId": "OG003", "value": "27.0"}, {"groupId": "OG004", "value": "44.6"}, {"groupId": "OG005", "value": "36.8"}]}]}]}, {"type": "SECONDARY", "title": "Occurrence of a Treat-to-target Response (HbA1c < 6.5%)", "description": "Occurrence of a Treat-to-target Response, defined as HbA1c \\< 6.5% over time", "populationDescription": "Treated set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Weeks 1, 6, 18, 30, 42, 54, 66 and 78", "groups": [{"id": "OG000", "title": "Empagliflozin 10 mg", "description": "Patients receive 10 mg Empagliflozin in tablets once daily."}, {"id": "OG001", "title": "Empagliflozin 25 mg", "description": "Patients receive 25 mg Empagliflozin in tablets once daily."}, {"id": "OG002", "title": "Metformin", "description": "Patients receive between 1000 and 2000 mg Metformin daily as monotherapy. Patients on metformin as active comparator (from trial NCT00789035) were to take their medication according to the instruction of their investigator, continuing the maximum tolerated dose determined in the preceding trial."}, {"id": "OG003", "title": "Empagliflozin 10 mg + Metformin", "description": "Patients receive 10 mg Empagliflozin in tablets once daily added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}, {"id": "OG004", "title": "Empagliflozin 25 mg + Metformin", "description": "Patients receive 25 mg Empagliflozin in tablets once daily added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}, {"id": "OG005", "title": "Sitaglipin + Metformin", "description": "Patients receive 100 mg Sitagliptin once daily in tablets added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "109"}, {"groupId": "OG002", "value": "56"}, {"groupId": "OG003", "value": "166"}, {"groupId": "OG004", "value": "166"}, {"groupId": "OG005", "value": "56"}]}], "classes": [{"title": "Week 6 (N=104, 108, 55, 162, 163, 54)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.8"}, {"groupId": "OG001", "value": "11.1"}, {"groupId": "OG002", "value": "16.4"}, {"groupId": "OG003", "value": "6.2"}, {"groupId": "OG004", "value": "6.7"}, {"groupId": "OG005", "value": "11.1"}]}]}, {"title": "Week 18 (N=93, 105, 53, 149, 157, 48)", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.8"}, {"groupId": "OG001", "value": "12.4"}, {"groupId": "OG002", "value": "13.2"}, {"groupId": "OG003", "value": "4.7"}, {"groupId": "OG004", "value": "5.1"}, {"groupId": "OG005", "value": "12.5"}]}]}, {"title": "Week 30 (N=93, 99, 50, 140, 151, 45)", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.6"}, {"groupId": "OG001", "value": "10.1"}, {"groupId": "OG002", "value": "14.0"}, {"groupId": "OG003", "value": "8.6"}, {"groupId": "OG004", "value": "10.6"}, {"groupId": "OG005", "value": "4.4"}]}]}, {"title": "Week 42 (N=85, 93, 46, 132, 140, 44)", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.8"}, {"groupId": "OG001", "value": "10.8"}, {"groupId": "OG002", "value": "21.7"}, {"groupId": "OG003", "value": "10.6"}, {"groupId": "OG004", "value": "21.4"}, {"groupId": "OG005", "value": "9.1"}]}]}, {"title": "Week 54 (N=78, 85, 44, 128, 136, 41)", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.5"}, {"groupId": "OG001", "value": "5.9"}, {"groupId": "OG002", "value": "18.2"}, {"groupId": "OG003", "value": "10.9"}, {"groupId": "OG004", "value": "15.4"}, {"groupId": "OG005", "value": "9.8"}]}]}, {"title": "Week 66 (N=80, 87, 43, 120, 127, 39)", "categories": [{"measurements": [{"groupId": "OG000", "value": "10.0"}, {"groupId": "OG001", "value": "11.5"}, {"groupId": "OG002", "value": "14.0"}, {"groupId": "OG003", "value": "8.3"}, {"groupId": "OG004", "value": "12.6"}, {"groupId": "OG005", "value": "15.4"}]}]}, {"title": "Week 78 (N=72, 84, 42, 115, 121, 38)", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.9"}, {"groupId": "OG001", "value": "8.3"}, {"groupId": "OG002", "value": "9.5"}, {"groupId": "OG003", "value": "10.4"}, {"groupId": "OG004", "value": "13.2"}, {"groupId": "OG005", "value": "18.4"}]}]}]}, {"type": "SECONDARY", "title": "Occurrence of a Relative Efficacy Response", "description": "Occurrence of a Relative Efficacy Response (HbA1c Lowered by at least \\>=0.5% over time)", "populationDescription": "Treated set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Weeks 1, 6, 18, 30, 42, 54, 66 and 78", "groups": [{"id": "OG000", "title": "Empagliflozin 10 mg", "description": "Patients receive 10 mg Empagliflozin in tablets once daily."}, {"id": "OG001", "title": "Empagliflozin 25 mg", "description": "Patients receive 25 mg Empagliflozin in tablets once daily."}, {"id": "OG002", "title": "Metformin", "description": "Patients receive between 1000 and 2000 mg Metformin daily as monotherapy. Patients on metformin as active comparator (from trial NCT00789035) were to take their medication according to the instruction of their investigator, continuing the maximum tolerated dose determined in the preceding trial."}, {"id": "OG003", "title": "Empagliflozin 10 mg + Metformin", "description": "Patients receive 10 mg Empagliflozin in tablets once daily added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}, {"id": "OG004", "title": "Empagliflozin 25 mg + Metformin", "description": "Patients receive 25 mg Empagliflozin in tablets once daily added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}, {"id": "OG005", "title": "Sitaglipin + Metformin", "description": "Patients receive 100 mg Sitagliptin once daily in tablets added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "109"}, {"groupId": "OG002", "value": "56"}, {"groupId": "OG003", "value": "166"}, {"groupId": "OG004", "value": "166"}, {"groupId": "OG005", "value": "56"}]}], "classes": [{"title": "Week 6 (N=104, 108, 55, 162, 163, 54)", "categories": [{"measurements": [{"groupId": "OG000", "value": "42.3"}, {"groupId": "OG001", "value": "50.9"}, {"groupId": "OG002", "value": "80.0"}, {"groupId": "OG003", "value": "41.4"}, {"groupId": "OG004", "value": "56.4"}, {"groupId": "OG005", "value": "63.0"}]}]}, {"title": "Week 18 (N=93, 105, 53, 149, 157, 48)", "categories": [{"measurements": [{"groupId": "OG000", "value": "51.6"}, {"groupId": "OG001", "value": "61.9"}, {"groupId": "OG002", "value": "77.4"}, {"groupId": "OG003", "value": "53.7"}, {"groupId": "OG004", "value": "61.8"}, {"groupId": "OG005", "value": "66.7"}]}]}, {"title": "Week 30 (N=93, 99, 50, 140, 151, 45)", "categories": [{"measurements": [{"groupId": "OG000", "value": "50.5"}, {"groupId": "OG001", "value": "55.6"}, {"groupId": "OG002", "value": "78.0"}, {"groupId": "OG003", "value": "55.0"}, {"groupId": "OG004", "value": "63.6"}, {"groupId": "OG005", "value": "68.9"}]}]}, {"title": "Week 42 (N=85, 93, 46, 132, 140, 44)", "categories": [{"measurements": [{"groupId": "OG000", "value": "58.8"}, {"groupId": "OG001", "value": "60.2"}, {"groupId": "OG002", "value": "82.6"}, {"groupId": "OG003", "value": "62.1"}, {"groupId": "OG004", "value": "66.4"}, {"groupId": "OG005", "value": "54.5"}]}]}, {"title": "Week 54 (N=78, 85, 44, 128, 136, 41)", "categories": [{"measurements": [{"groupId": "OG000", "value": "62.8"}, {"groupId": "OG001", "value": "58.8"}, {"groupId": "OG002", "value": "81.8"}, {"groupId": "OG003", "value": "59.4"}, {"groupId": "OG004", "value": "65.4"}, {"groupId": "OG005", "value": "58.5"}]}]}, {"title": "Week 66 (N=80, 87, 43, 120, 127, 39)", "categories": [{"measurements": [{"groupId": "OG000", "value": "53.8"}, {"groupId": "OG001", "value": "56.3"}, {"groupId": "OG002", "value": "76.7"}, {"groupId": "OG003", "value": "55.0"}, {"groupId": "OG004", "value": "64.6"}, {"groupId": "OG005", "value": "66.7"}]}]}, {"title": "Week 78 (N=72, 84, 42, 115, 121, 38)", "categories": [{"measurements": [{"groupId": "OG000", "value": "50.0"}, {"groupId": "OG001", "value": "50.0"}, {"groupId": "OG002", "value": "66.7"}, {"groupId": "OG003", "value": "56.5"}, {"groupId": "OG004", "value": "64.5"}, {"groupId": "OG005", "value": "60.5"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) Over Time", "description": "Baseline source: before first intake of active treatment (preceding trial or Open label extension)", "populationDescription": "Treated set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Weeks 1, 6, 18, 30, 42, 54, 66 and 78", "groups": [{"id": "OG000", "title": "Empagliflozin 10 mg", "description": "Patients receive 10 mg Empagliflozin in tablets once daily."}, {"id": "OG001", "title": "Empagliflozin 25 mg", "description": "Patients receive 25 mg Empagliflozin in tablets once daily."}, {"id": "OG002", "title": "Metformin", "description": "Patients receive between 1000 and 2000 mg Metformin daily as monotherapy. Patients on metformin as active comparator (from trial NCT00789035) were to take their medication according to the instruction of their investigator, continuing the maximum tolerated dose determined in the preceding trial."}, {"id": "OG003", "title": "Empagliflozin 10 mg + Metformin", "description": "Patients receive 10 mg Empagliflozin in tablets once daily added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}, {"id": "OG004", "title": "Empagliflozin 25 mg + Metformin", "description": "Patients receive 25 mg Empagliflozin in tablets once daily added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}, {"id": "OG005", "title": "Sitaglipin + Metformin", "description": "Patients receive 100 mg Sitagliptin once daily in tablets added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "109"}, {"groupId": "OG002", "value": "56"}, {"groupId": "OG003", "value": "166"}, {"groupId": "OG004", "value": "166"}, {"groupId": "OG005", "value": "56"}]}], "classes": [{"title": "Week 6 (N=102, 108, 55, 156, 160, 53)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-30.6", "spread": "42.5"}, {"groupId": "OG001", "value": "-35.8", "spread": "39.6"}, {"groupId": "OG002", "value": "-29.9", "spread": "40.0"}, {"groupId": "OG003", "value": "-25.7", "spread": "35.2"}, {"groupId": "OG004", "value": "-36.7", "spread": "36.3"}, {"groupId": "OG005", "value": "-32.6", "spread": "42.4"}]}]}, {"title": "Week 18 (N=94, 103, 51, 144, 153, 45)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-35.5", "spread": "37.9"}, {"groupId": "OG001", "value": "-33.7", "spread": "42.0"}, {"groupId": "OG002", "value": "-30.4", "spread": "40.3"}, {"groupId": "OG003", "value": "-30.6", "spread": "31.6"}, {"groupId": "OG004", "value": "-37.6", "spread": "35.8"}, {"groupId": "OG005", "value": "-16.7", "spread": "44.0"}]}]}, {"title": "Week 30 (N=92, 101, 51, 133, 147, 43)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-32.3", "spread": "41.4"}, {"groupId": "OG001", "value": "-35.0", "spread": "39.6"}, {"groupId": "OG002", "value": "-28.5", "spread": "28.9"}, {"groupId": "OG003", "value": "-29.9", "spread": "34.9"}, {"groupId": "OG004", "value": "-37.9", "spread": "38.6"}, {"groupId": "OG005", "value": "-25.6", "spread": "38.6"}]}]}, {"title": "Week 42 (N=85, 93, 46, 126, 140, 42)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-35.8", "spread": "39.1"}, {"groupId": "OG001", "value": "-31.3", "spread": "41.4"}, {"groupId": "OG002", "value": "-31.0", "spread": "35.6"}, {"groupId": "OG003", "value": "-30.8", "spread": "36.4"}, {"groupId": "OG004", "value": "-36.8", "spread": "34.1"}, {"groupId": "OG005", "value": "-18.5", "spread": "43.1"}]}]}, {"title": "Week 54 (N=80, 88, 44, 124, 134, 39)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-32.1", "spread": "37.2"}, {"groupId": "OG001", "value": "-31.0", "spread": "37.8"}, {"groupId": "OG002", "value": "-31.8", "spread": "35.9"}, {"groupId": "OG003", "value": "-28.2", "spread": "33.7"}, {"groupId": "OG004", "value": "-36.8", "spread": "32.5"}, {"groupId": "OG005", "value": "-29.4", "spread": "35.4"}]}]}, {"title": "Week 66 (N=80, 86, 43, 116, 125, 38)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-28.0", "spread": "41.4"}, {"groupId": "OG001", "value": "-28.6", "spread": "42.6"}, {"groupId": "OG002", "value": "-26.4", "spread": "35.7"}, {"groupId": "OG003", "value": "-21.7", "spread": "36.2"}, {"groupId": "OG004", "value": "-29.6", "spread": "36.4"}, {"groupId": "OG005", "value": "-32.5", "spread": "46.9"}]}]}, {"title": "Week 78 (N=72, 84, 43, 112, 121, 36)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-27.9", "spread": "33.1"}, {"groupId": "OG001", "value": "-25.4", "spread": "40.9"}, {"groupId": "OG002", "value": "-22.9", "spread": "39.7"}, {"groupId": "OG003", "value": "-24.7", "spread": "41.5"}, {"groupId": "OG004", "value": "-31.9", "spread": "36.5"}, {"groupId": "OG005", "value": "-25.7", "spread": "48.9"}]}]}]}, {"type": "PRIMARY", "title": "Clinical Relevant Abnormalities for Physical Examination, Vital Signs, ECG and Laboratory Measurements", "description": "Clinical Relevant Abnormalities for Physical Examination, Vital Signs, ECG and Laboratory Measurements. New abnormal findings or worsening of baseline conditions were reported as treatment related Adverse Events.", "populationDescription": "Treated set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "78 weeks plus 1 week of follow-up", "groups": [{"id": "OG000", "title": "Empagliflozin 10 mg", "description": "Patients receive 10 mg Empagliflozin in tablets once daily."}, {"id": "OG001", "title": "Empagliflozin 25 mg", "description": "Patients receive 25 mg Empagliflozin in tablets once daily."}, {"id": "OG002", "title": "Metformin", "description": "Patients receive between 1000 and 2000 mg Metformin daily as monotherapy. Patients on metformin as active comparator (from trial NCT00789035) were to take their medication according to the instruction of their investigator, continuing the maximum tolerated dose determined in the preceding trial."}, {"id": "OG003", "title": "Empagliflozin 10 mg + Metformin", "description": "Patients receive 10 mg Empagliflozin in tablets once daily added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}, {"id": "OG004", "title": "Empagliflozin 25 mg + Metformin", "description": "Patients receive 25 mg Empagliflozin in tablets once daily added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}, {"id": "OG005", "title": "Sitaglipin + Metformin", "description": "Patients receive 100 mg Sitagliptin once daily in tablets added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "109"}, {"groupId": "OG002", "value": "56"}, {"groupId": "OG003", "value": "166"}, {"groupId": "OG004", "value": "166"}, {"groupId": "OG005", "value": "56"}]}], "classes": [{"title": "Alanine aminotransferase increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.9"}, {"groupId": "OG001", "value": "0.9"}, {"groupId": "OG002", "value": "3.6"}, {"groupId": "OG003", "value": "0.6"}, {"groupId": "OG004", "value": "0.6"}, {"groupId": "OG005", "value": "1.8"}]}]}, {"title": "Aspartate aminotransferase increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.9"}, {"groupId": "OG001", "value": "0.0"}, {"groupId": "OG002", "value": "1.8"}, {"groupId": "OG003", "value": "0.0"}, {"groupId": "OG004", "value": "0.6"}, {"groupId": "OG005", "value": "0.0"}]}]}, {"title": "Gamma-glutamyltransferase increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.9"}, {"groupId": "OG001", "value": "0.0"}, {"groupId": "OG002", "value": "1.8"}, {"groupId": "OG003", "value": "0.0"}, {"groupId": "OG004", "value": "1.2"}, {"groupId": "OG005", "value": "0.0"}]}]}, {"title": "Blood alkaline phosphatase increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.9"}, {"groupId": "OG001", "value": "0.0"}, {"groupId": "OG002", "value": "0.0"}, {"groupId": "OG003", "value": "0.0"}, {"groupId": "OG004", "value": "0.0"}, {"groupId": "OG005", "value": "0.0"}]}]}, {"title": "Blood creatine phosphokinase increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.9"}, {"groupId": "OG001", "value": "0.0"}, {"groupId": "OG002", "value": "0.0"}, {"groupId": "OG003", "value": "0.0"}, {"groupId": "OG004", "value": "0.0"}, {"groupId": "OG005", "value": "0.0"}]}]}, {"title": "Granulocyte count decreased", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.9"}, {"groupId": "OG001", "value": "0.0"}, {"groupId": "OG002", "value": "0.0"}, {"groupId": "OG003", "value": "0.0"}, {"groupId": "OG004", "value": "0.0"}, {"groupId": "OG005", "value": "0.0"}]}]}, {"title": "Hepatic enzyme increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}, {"groupId": "OG001", "value": "0.9"}, {"groupId": "OG002", "value": "0.0"}, {"groupId": "OG003", "value": "0.6"}, {"groupId": "OG004", "value": "0.0"}, {"groupId": "OG005", "value": "0.0"}]}]}, {"title": "Blood creatinine increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.9"}, {"groupId": "OG001", "value": "0.9"}, {"groupId": "OG002", "value": "0.0"}, {"groupId": "OG003", "value": "0.0"}, {"groupId": "OG004", "value": "0.6"}, {"groupId": "OG005", "value": "0.0"}]}]}, {"title": "Creatinine renal clearance decreased", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}, {"groupId": "OG001", "value": "0.0"}, {"groupId": "OG002", "value": "0.0"}, {"groupId": "OG003", "value": "0.6"}, {"groupId": "OG004", "value": "0.0"}, {"groupId": "OG005", "value": "0.0"}]}]}, {"title": "Weight decreased", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}, {"groupId": "OG001", "value": "0.9"}, {"groupId": "OG002", "value": "0.0"}, {"groupId": "OG003", "value": "0.0"}, {"groupId": "OG004", "value": "0.6"}, {"groupId": "OG005", "value": "0.0"}]}]}, {"title": "Sick sinus syndrome", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.9"}, {"groupId": "OG001", "value": "0.0"}, {"groupId": "OG002", "value": "0.0"}, {"groupId": "OG003", "value": "0.0"}, {"groupId": "OG004", "value": "0.0"}, {"groupId": "OG005", "value": "0.0"}]}]}, {"title": "Tachycardia", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.9"}, {"groupId": "OG001", "value": "1.8"}, {"groupId": "OG002", "value": "0.0"}, {"groupId": "OG003", "value": "0.6"}, {"groupId": "OG004", "value": "0.6"}, {"groupId": "OG005", "value": "0.0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From drug administration until 7 days after the last intake of study drug, up to 582 days", "eventGroups": [{"id": "EG000", "title": "Empagliflozin 10 mg", "description": "Patients receive 10 mg Empagliflozin in tablets once daily.", "seriousNumAffected": 10, "seriousNumAtRisk": 106, "otherNumAffected": 34, "otherNumAtRisk": 106}, {"id": "EG001", "title": "Empagliflozin 25 mg", "description": "Patients receive 25 mg Empagliflozin in tablets once daily.", "seriousNumAffected": 7, "seriousNumAtRisk": 109, "otherNumAffected": 46, "otherNumAtRisk": 109}, {"id": "EG002", "title": "Metformin", "description": "Patients receive between 1000 and 2000 mg Metformin daily as monotherapy. Patients on metformin as active comparator (from trial NCT00789035) were to take their medication according to the instruction of their investigator, continuing the maximum tolerated dose determined in the preceding trial.", "seriousNumAffected": 3, "seriousNumAtRisk": 56, "otherNumAffected": 27, "otherNumAtRisk": 56}, {"id": "EG003", "title": "Empagliflozin 10 mg + Metformin", "description": "Patients receive 10 mg Empagliflozin in tablets once daily added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study.", "seriousNumAffected": 10, "seriousNumAtRisk": 166, "otherNumAffected": 74, "otherNumAtRisk": 166}, {"id": "EG004", "title": "Empagliflozin 25 mg + Metformin", "description": "Patients receive 25 mg Empagliflozin in tablets once daily added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study.", "seriousNumAffected": 13, "seriousNumAtRisk": 166, "otherNumAffected": 79, "otherNumAtRisk": 166}, {"id": "EG005", "title": "Sitaglipin + Metformin", "description": "Patients receive 100 mg Sitagliptin once daily in tablets added to metformin background. Patients on metformin background (from trial NCT00749190) continued with their standard metformin therapy throughout the entire study.", "seriousNumAffected": 9, "seriousNumAtRisk": 56, "otherNumAffected": 26, "otherNumAtRisk": 56}], "seriousEvents": [{"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Anal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Post procedural infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Cervix carcinoma recurrent", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 56}]}, {"term": "Refractory cytopenia with multilineage dysplasia", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 56}]}, {"term": "Transitional cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 56}]}, {"term": "Bile duct cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Chronic lymphocytic leukaemia", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Goitre", "organSystem": "Endocrine disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Thyroid cyst", "organSystem": "Endocrine disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 2, "numAtRisk": 56}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 2, "numAtRisk": 56}]}, {"term": "Aphasia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 56}]}, {"term": "Hemiplegia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 56}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 56}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Carotid artery stenosis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Visual acuity reduced", "organSystem": "Eye disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 56}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 56}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Acute respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 56}]}, {"term": "Colonic polyp", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 56}]}, {"term": "Abdominal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Anal fistula", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Gingival cyst", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Lumbar hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 2, "numAtRisk": 56}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 56}]}, {"term": "Bile duct obstruction", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Spinal osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 56}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Rotator cuff syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Urinary retention", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Benign prostatic hyperplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Traumatic fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Fibula fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Ligament rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Post procedural haematuria", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Vascular graft occlusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Wrist fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Concussion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Burns second degree", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Meniscus lesion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Post procedural haematoma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Hysterectomy", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Abortion induced", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 9, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 12, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 15, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 5, "numAtRisk": 56}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 12, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 18, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 5, "numAtRisk": 56}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 8, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 6, "numAtRisk": 56}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 56}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 36, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 25, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 9, "numAtRisk": 56}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 6, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 3, "numAtRisk": 56}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 7, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 56}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 4, "numAtRisk": 56}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 6, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 4, "numAtRisk": 56}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 4, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 56}]}, {"term": "Benign prostatic hyperplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 3, "numAtRisk": 56}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 56}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MEDDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 56}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG005", "numAffected": 3, "numAtRisk": 56}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract."}, "pointOfContact": {"title": "Boehringer Ingelheim Call Center", "organization": "Boehringer Ingelheim Pharmaceuticals", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Argentina"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}, {"id": "C000570240", "term": "Empagliflozin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}], "browseLeaves": [{"id": "M258082", "name": "Empagliflozin", "asFound": "Thalidomide", "relevance": "HIGH"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}